UNSPSC 51333201: Aldesleukin

This classification denotes a therapeutic interleukin-2 with the molecular formula C690H1115N177O202S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M89N0Q7EQR, more generally known as aldesleukin. European Medicines Agency schedules aldesleukin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05303MIG. The term ALDESLEUKIN is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 5, no. 3 1991, list 31.

Most nations schedule aldesleukin under HS 35040000 and SITC 59225. As of Q4 2014, ALDESLEUKIN remains the US FDA Preferred Term for this commodity. Aldesleukin bears US NLM identifiers UMLS ID C0218986 and NCI Concept Code C1498. SMILES: NONE.

UNSPSC 51333201 Aldesleukin, a Commodity code, shows minimal direct activity but appears in state and local procurement systems tagged alongside naloxone, drug deactivation systems, and generic multi-source pharmaceuticals. The code nominally covers a specific immunotherapy agent (aldesleukin), yet the recent solicitations under this tag involve broader pharmaceutical procurement — naloxone distribution, direct-to-manufacturer prescription programs, and generic OTC product supply agreements. State and local governments are buying pharmaceutical products and related health-delivery systems through competitive bidding and cooperative purchasing vehicles, with issuing bodies including county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The mismatch between the code's nominal scope and actual recent solicitation content suggests either tagging error or that aldesleukin itself generates minimal stand-alone procurement activity in the state and local market.

Geographic activity centers on Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS) on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) posted January 20, 2026, with a response deadline of March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendor compliance with cGMP, the Drug Supply Chain Security Act, and pricing through authorized wholesalers. These solicitations suggest that the code's actual use in state and local procurement centers on pharmaceutical distribution and supply-chain management rather than aldesleukin specifically.